He concluded that "these criteria are not ready for clinical use. Nevertheless, this new approach should quickly be Alzheimer's disease opted following standardization and validation."
Although "much work remains," Dr. Foster urged that "we seize this opportunity to reopen the discussion of Alzheimer's disease diagnosis."
|The international working group conference was sponsored through a grant-in-aid received from Eisai, Janssen-Cilag, Novartis, and Servier. Dr. Dubois declared no conflicts. Dr. Foster said he was a consultant to GE HealthCare, and Myriad Pharmaceuticals, and an investigator in clinical trials sponsored by Merck & Co., and Myriad.|
Primary source: Lancet Neurology
Source reference: Dubois B et al "Research criteria for the diagnosis of Alzheimer's disease revising the NINCDS-ADRDA criteria" Lancet Neurology 2007; Published online July 9, 2007 DOI:10.1016/S1474-4422 (07)70178-3.